Quick Answer
ARS Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $41.32 million for the year ending 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -18.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $374.21 million | Q2 2021: $359.69 million | Q3 2021: $300.66 million | Q1 2022: $233.99 million | Q2 2022: $218.69 million | Q3 2022: $203.22 million | Q1 2023: $87.86 million | Q2 2023: $119.02 million | Q3 2023: $60.53 million | Q1 2024: $56.01 million | Q2 2024: $36.63 million | Q3 2024: $39.66 million | Q1 2025: $39.86 million | Q2 2025: $51.54 million | Q3 2025: $59.56 million.
- Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 89.3%.
- Historical annual values: Fiscal year 2025: $41.32 million | Fiscal year 2024: $50.82 million | Fiscal year 2023: $70.97 million | Fiscal year 2022: $210.52 million | Fiscal year 2021: $60.06 million | Fiscal year 2020: $386.57 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: